Abstract
Expanding treatment options for non-small cell lung cancer (NSCLC) are moving to lower stages of the disease based on the results of clinical studies, which is reflected in the updated ESMO guidelines for the treatment of early and locally advanced NSCLC. For inoperable stage III NSCLC, a multimodal approach, including immunotherapy, is the key, as shown by the updated results of the PACIFIC study.